Health Care

GRAIL’s upcoming J.P. Morgan Healthcare Conference presentation highlights its pioneering Galleri and DAC tests, showcasing breakthroughs in early cancer detection and growth‑stage financial outlook.

NovaBay Pharmaceuticals acquisition by Tata Chemicals

Adaptimmune Therapeutics: a UK biotech pioneer in T‑cell receptor cancer therapies, exploring volatile stock trends and long‑term R&D prospects.

Shanghai Fosun Pharmaceutical’s recent equity investment and strong 2025‑26 performance reveal a resilient, growth‑oriented pharma leader poised to innovate and capture market share.

Harrow Inc. focuses on ophthalmic drugs, trading at $51 on Nasdaq with a high P/B of 39 and negative earnings, yet a $1.7 billion market cap hints at future growth.

Explore Sana Biotechnology’s recent analyst upgrade, conference spotlight, and engineered‑cell therapy progress—what it means for investors and the market.

Explore Bristol‑Myers Squibb’s rising analyst support, $60 price target bump, and 17.3% six‑month rally—why BMY’s stock may soon hit its $63.33 high.

Discover how AstraZeneca’s new U.S. biopharma leadership and Nasdaq‑100 exit sharpen growth focus and boost shareholder value.

Explore Madrigal Pharmaceuticals’ biotech ambitions and the shockingly negative P/E, volatile stock, and high market cap that raise red flags for investors.

Viking Therapeutics hits enrollment milestones for its obesity therapy, hires a top commercial leader, and earns strong analyst support, positioning for future regulatory progress and potential upside.